Literature DB >> 1374149

Reversal of radiation-induced neutropenia by granulocyte colony-stimulating factor.

L B Marks1, H S Friedman, J Kurtzberg, W J Oakes, B M Hockenberger.   

Abstract

Myelosuppression is a common sequelae of radiotherapy, occasionally delaying the completion of treatment. In this report, we describe successful reversal of radiation-induced neutropenia in a child receiving craniospinal irradiation by granulocyte colony-stimulating factor (G-CSF). We suggest that G-CSF be considered as supportive care in patients in whom neutropenia develops during radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374149     DOI: 10.1002/mpo.2950200312

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  6 in total

1.  [Comparison of 2 strategies in the treatment of radiogenic leukopenia using granulocyte colony stimulating factor].

Authors:  I A Adamietz; B Rosskopf; F D Dapper; H von Lieven; H D Böttcher
Journal:  Strahlenther Onkol       Date:  1997-03       Impact factor: 3.621

2.  Impact of acute hematological toxicity on treatment interruptions during cranio-spinal irradiation in medulloblastoma: a tertiary care institute experience.

Authors:  Narendra Kumar; Raviteja Miriyala; Pragyat Thakur; Renu Madan; Pravin Salunke; Budhi Yadav; Ankita Gupta
Journal:  J Neurooncol       Date:  2017-06-02       Impact factor: 4.130

3.  [G-CSF in radiochemotherapy].

Authors:  M Riepl; R Fietkau; R Sauer
Journal:  Strahlenther Onkol       Date:  1997-02       Impact factor: 3.621

4.  Omeprazole-induced blood dyscrasia in a clozapine-treated patient.

Authors:  Robert J Philipps; Tammie Lee Demler; Claudia Lee
Journal:  Innov Clin Neurosci       Date:  2012-09

Review 5.  [Use of G-CSF (Neupogen) in multimodal treatment in radiotherapy].

Authors:  O Bartzsch; M Riepl; M Busch; G Michael; M Allgäuer; A C Voss; R Sauer; E Dühmke; G Gademann; M Molls
Journal:  Strahlenther Onkol       Date:  1998-11       Impact factor: 3.621

Review 6.  Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.

Authors:  J E Frampton; C R Lee; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.